Novo Nordisk announces REDEFINE 1 trial of CagriSema met co-primary endpoints

The New England Journal of Medicine, NEJM, published results from Novo Nordisk’s (NVO) phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes. REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo. These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s, ADA, 85th Scientific Sessions and published in NEJM. When adhering to treatment, weight loss of greater than or equal to 5%, greater than or equal to20%, greater than or equal to25%, and greater than or equal to30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks